CY1111088T1 - Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση - Google Patents
Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωσηInfo
- Publication number
- CY1111088T1 CY1111088T1 CY20101101027T CY101101027T CY1111088T1 CY 1111088 T1 CY1111088 T1 CY 1111088T1 CY 20101101027 T CY20101101027 T CY 20101101027T CY 101101027 T CY101101027 T CY 101101027T CY 1111088 T1 CY1111088 T1 CY 1111088T1
- Authority
- CY
- Cyprus
- Prior art keywords
- controlled
- tolterodin
- liberty
- administration
- pharmaceutical form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Μέθοδος και τυποποίηση για θεραπεία ασταθούς ή υπερδραστικής ουροδόχου κύστης, όπου τολτεροδίνη ή σχετική με τολτεροδίνη ένωση ή φαρμακευτικώς αποδεκτό άλας αυτής χορηγείται σε έναν ασθενή σε μια φαρμακευτικώς αποτελεσματική ποσότητα αυτής μέσω φαρμακοτεχνικής μορφής ελεγχόμενης απελευθέρωσης που χορηγεί τολτεροδίνη ή την εν λόγω σχετική με τολτεροδίνη ένωση ή άλας αυτής με ελεγχόμενο ρυθμό για τουλάχιστον 24 ώρες.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802864A SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| SE9803871A SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Therapeutic method and formulation |
| EP99946521A EP1039882B1 (en) | 1998-08-27 | 1999-08-26 | Therapeutic formulation for administering tolterodine with controlled release |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111088T1 true CY1111088T1 (el) | 2015-06-11 |
Family
ID=26663376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101101027T CY1111088T1 (el) | 1998-08-27 | 2010-11-17 | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6770295B1 (el) |
| EP (2) | EP2153825A1 (el) |
| CN (1) | CN1239152C (el) |
| AP (1) | AP1529A (el) |
| AR (1) | AR029311A1 (el) |
| AT (1) | ATE487471T1 (el) |
| AU (1) | AU745190B2 (el) |
| BG (1) | BG65168B1 (el) |
| CA (1) | CA2311755C (el) |
| CY (1) | CY1111088T1 (el) |
| CZ (1) | CZ302630B6 (el) |
| DE (1) | DE69942928D1 (el) |
| DK (1) | DK1039882T3 (el) |
| EA (1) | EA002720B1 (el) |
| GE (1) | GEP20043354B (el) |
| HK (1) | HK1034664A1 (el) |
| HU (1) | HUP0100437A3 (el) |
| ID (1) | ID25824A (el) |
| IL (1) | IL136294A (el) |
| IS (1) | IS2976B (el) |
| ME (1) | ME00850B (el) |
| MY (1) | MY127946A (el) |
| NO (1) | NO329830B1 (el) |
| NZ (1) | NZ504618A (el) |
| OA (1) | OA11636A (el) |
| PT (1) | PT1039882E (el) |
| SI (1) | SI1039882T1 (el) |
| SK (1) | SK287111B6 (el) |
| TR (1) | TR200001998T1 (el) |
| UA (1) | UA72882C2 (el) |
| WO (1) | WO2000012069A1 (el) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE19922662C1 (de) * | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
| DE19932651A1 (de) * | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
| WO2001034139A1 (en) * | 1999-11-11 | 2001-05-17 | Pharmacia Ab | Pharmaceutical formulation containing tolterodine and its use |
| DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
| US20030185882A1 (en) | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| MXPA04003866A (es) * | 2001-11-09 | 2004-07-08 | Pharmacia Ab | Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva. |
| US6773421B2 (en) | 2001-12-14 | 2004-08-10 | Kimberly-Clark Worlwide, Inc. | Combination for managing the involuntary loss of bladder control |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| ATE465725T1 (de) * | 2002-12-13 | 2010-05-15 | Warner Lambert Co | Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege |
| WO2004064821A1 (en) † | 2003-01-22 | 2004-08-05 | Pfizer Health Ab | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| WO2004105735A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical compositions of tolterodine and processes for their preparation |
| JP5610663B2 (ja) | 2003-11-04 | 2014-10-22 | スパーナス ファーマシューティカルズ インコーポレイテッド | トロスピウムの１日１回剤形 |
| CA2536401C (en) | 2003-11-04 | 2011-08-30 | Shire Laboratories Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| WO2005105036A1 (en) * | 2004-04-28 | 2005-11-10 | Natco Pharma Limited | Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation |
| EP1629834A1 (en) * | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| EP1874282B1 (en) * | 2005-04-06 | 2010-09-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
| CN1330297C (zh) * | 2005-07-04 | 2007-08-08 | 宛六一 | 酒石酸托特罗定软胶囊及其制备方法 |
| KR20070012205A (ko) * | 2005-07-22 | 2007-01-25 | 주식회사종근당 | 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛 |
| JP5869745B2 (ja) | 2006-02-03 | 2016-02-24 | プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー | ２５−ヒドロキシビタミンｄ２及び２５−ヒドロキシビタミンｄ３によるビタミンｄ不足及び欠乏の治療 |
| WO2007122015A1 (en) * | 2006-04-21 | 2007-11-01 | Synthon B.V. | Tolterodine beads |
| EP2679228B1 (en) | 2006-06-21 | 2018-03-21 | Opko Ireland Global Holdings, Ltd. | Therapy using vitamin D repletion agent and vitamin D hormone replacement agent |
| US20100144684A1 (en) | 2007-04-25 | 2010-06-10 | Proventiv Therapeutics, Inc. | Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease |
| DK3342405T3 (da) | 2007-04-25 | 2019-11-11 | Opko Ireland Global Holdings Ltd | Kontrolleret frigivelse af 25-hydroxyvitamin d |
| PT2148684E (pt) | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
| CL2008001970A1 (es) * | 2007-07-03 | 2009-03-27 | Synthon Bv | Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva. |
| US8486452B2 (en) | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
| EP2175843B1 (en) | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| US20090192228A1 (en) * | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
| EP2281058B1 (en) | 2008-04-02 | 2016-06-29 | Opko Ireland Global Holdings, Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
| TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| KR101004205B1 (ko) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
| WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
| KR101746204B1 (ko) * | 2010-02-18 | 2017-06-13 | 에스케이케미칼주식회사 | 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물 |
| ES2783980T3 (es) | 2010-03-29 | 2020-09-21 | Opko Ireland Global Holdings Ltd | Métodos y composiciones para la reducción de niveles de paratiroides |
| EP2563123B1 (en) | 2010-04-30 | 2018-04-25 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| WO2012017892A1 (ja) * | 2010-08-03 | 2012-02-09 | 久光製薬株式会社 | 貼付剤及びその粘着力増強方法 |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| TW202214257A (zh) | 2016-03-28 | 2022-04-16 | 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 | 維生素d治療之方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| KR950701516A (ko) * | 1992-05-13 | 1995-04-28 | 에드워드 엘. 만델 | 옥시부티닌의 경피 투여(Transdermal Administration of Oxybutynin) |
| SE9203318D0 (sv) | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| AU7994694A (en) * | 1994-10-21 | 1996-05-15 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
| US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| WO1998003067A1 (en) | 1996-07-19 | 1998-01-29 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| EP0927034A1 (en) * | 1996-09-19 | 1999-07-07 | American Home Products Corporation | Method of treating urinary incontinence |
-
1999
- 1999-08-26 NZ NZ504618A patent/NZ504618A/xx not_active IP Right Cessation
- 1999-08-26 AT AT99946521T patent/ATE487471T1/de active
- 1999-08-26 IL IL13629499A patent/IL136294A/en unknown
- 1999-08-26 CZ CZ20001924A patent/CZ302630B6/cs not_active IP Right Cessation
- 1999-08-26 MY MYPI99003665A patent/MY127946A/en unknown
- 1999-08-26 AP APAP/P/2000/001823A patent/AP1529A/en active
- 1999-08-26 GE GE3951A patent/GEP20043354B/en unknown
- 1999-08-26 SK SK749-2000A patent/SK287111B6/sk not_active IP Right Cessation
- 1999-08-26 EA EA200000468A patent/EA002720B1/ru not_active IP Right Cessation
- 1999-08-26 DE DE69942928T patent/DE69942928D1/de not_active Expired - Lifetime
- 1999-08-26 WO PCT/SE1999/001463 patent/WO2000012069A1/en active Application Filing
- 1999-08-26 AU AU58918/99A patent/AU745190B2/en not_active Expired
- 1999-08-26 SI SI9931050T patent/SI1039882T1/sl unknown
- 1999-08-26 US US09/582,498 patent/US6770295B1/en not_active Expired - Lifetime
- 1999-08-26 UA UA2000052950A patent/UA72882C2/uk unknown
- 1999-08-26 ID IDP20001006A patent/ID25824A/id unknown
- 1999-08-26 CA CA2311755A patent/CA2311755C/en not_active Expired - Lifetime
- 1999-08-26 EP EP09173927A patent/EP2153825A1/en not_active Withdrawn
- 1999-08-26 ME MEP-2001-331A patent/ME00850B/me unknown
- 1999-08-26 DK DK99946521.4T patent/DK1039882T3/da active
- 1999-08-26 CN CNB99801916XA patent/CN1239152C/zh not_active Expired - Lifetime
- 1999-08-26 HU HU0100437A patent/HUP0100437A3/hu unknown
- 1999-08-26 TR TR2000/01998T patent/TR200001998T1/xx unknown
- 1999-08-26 OA OA1200000309A patent/OA11636A/en unknown
- 1999-08-26 AR ARP990104280A patent/AR029311A1/es not_active Application Discontinuation
- 1999-08-26 PT PT99946521T patent/PT1039882E/pt unknown
- 1999-08-26 EP EP99946521A patent/EP1039882B1/en not_active Revoked
-
2000
- 2000-05-26 BG BG104476A patent/BG65168B1/bg unknown
- 2000-06-09 NO NO20002977A patent/NO329830B1/no not_active IP Right Cessation
- 2000-06-15 IS IS5537A patent/IS2976B/is unknown
-
2001
- 2001-07-12 HK HK01104868A patent/HK1034664A1/xx not_active IP Right Cessation
-
2010
- 2010-11-17 CY CY20101101027T patent/CY1111088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
| ATE306266T1 (de) | Verbesserte verabreichungstechnik für multiple medikamentengaben | |
| NO20022014L (no) | En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| ES2170069T3 (es) | 1-alfa-hidroxiprevitamina d para administracion oral. | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| RU94046316A (ru) | Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза | |
| CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
| DK0503440T3 (da) | Sumatriptanholdige lægemidler | |
| DE59102210D1 (de) | Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus. | |
| IT1196564B (it) | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche | |
| DK0754034T3 (da) | Brusende farmaceutiske formuleringer indeholdende biologisk nedbrydelige mikrokapsler med kontrolleret afgivelse | |
| KR970025615A (ko) | 암 전이 억제제 | |
| AR030039A1 (es) | Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento | |
| DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| IT1244636B (it) | Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento. | |
| KR910018348A (ko) | 술포닐아미노치환 비시클로환계 히드록삼산 유도체 | |
| BG106180A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| RU2004112422A (ru) | Роувастатин в преддеменционных состояниях | |
| KR930702985A (ko) | 식도암의 치료 | |
| KR890015743A (ko) | 근섬유아세포의 작용을 개선시키기 위한 tp-수용체 길항제의 용도 | |
| LV11524A (lv) | Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana | |
| KR930019207A (ko) | 카르니틴 결핍 hiv-혈청양성 환자 치료용 l-카르니틴의 용도 | |
| RU2006137657A (ru) | Применение производных камптотецина для лечения пролиферативных заболеваний с использованием схемы лечения с фиксированной дозой | |
| EE200100193A (et) | 3-(1H-imidasool-4-ülmetüül)-indaan-5-ol'i kasutamine intraspinaalselt, teekasiseselt või epiduraalselt manustatava ravimi tootmises |